The use of an impeded androgen—danazol—in the management of benign breast disorders

Ricardo H. Asch, Robert B. Greenblatt
In: American Journal of Obstetrics and Gynecology · 1977 · vol. 127(2) , pp. 130–134 · doi:10.1016/s0002-9378(16)33237-9 · PMID:831493 · W2413862892
article OA: closed CC0 ⤵ 27 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper investigates the effectiveness of danazol, an impeded androgen, in treating various benign breast conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol, an impeded androgen with moderate antigonadotropin properties, was administered to 58 patients with a variety of benign breast disorders. The disturbances were present from 3 months to 20 years; the ages ranged from 21 to 50 years. The dose varied from 100 to 400 mg. per day for 74 to 310 days, depending upon the severity of the disorder. Most of the patients had favorable responses: 44 (75.8 per cent) experienced complete relief of subjective discomfort with disappearance of clinical signs; 17 (65.3 per cent) of the 26 patients followed from 11 to 32 months after discontinued therapy, remained symptom-free, while the others experienced moderate to complete recurrence. Fifty per cent of the women did not menstrate while on medication. Side effects were few and transient.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (27)

Source provenance

openalex
last seen: 2026-05-10T10:46:37.739636+00:00
License: CC0 · commercial use OK